CCA
CSTL icon

Catalyst Capital Advisors’s Castle Biosciences CSTL Stock Holding History

Catalyst Capital Advisors’s Portfolio CSTL Stock Details CSTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-300
Closed -$5K – 320
2019
Q3 		$5K Buy
+300
New +$6.65K ﹤0.01% 395

Other funds holding CSTL

NAM
Nexpoint Asset Management Dallas, Texas $1.49B AUM 61.08% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
PCM
Portolan Capital Management Boston, Massachusetts $1.88B AUM 115.74% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Lord, Abbett & Co
Lord, Abbett & Co Jersey City, New Jersey $30.6B AUM 57.44% 1-Year Est. Return

Catalyst Capital Advisors's CSTL Position: Q4 2019 in Review

Catalyst Capital Advisors sold out of Castle Biosciences (CSTL) in Q4 2019, closing a stake of 300 shares — an estimated $5K sold.

Catalyst Capital Advisors first reported a position in CSTL in Q3 2019 and held it in 1 quarter. The position peaked at $5K in Q3 2019. 67 funds tracked by Wall St. Rank hold CSTL as of Q4 2019.

  • Catalyst Capital Advisors reported no remaining Castle Biosciences position as of Q4 2019 after selling out during the quarter.
  • Catalyst Capital Advisors sold 300 Castle Biosciences shares in Q4 2019, an estimated $5K.
  • Catalyst Capital Advisors first reported a position in Castle Biosciences in Q3 2019 and held it in 1 quarter.
  • Catalyst Capital Advisors's Castle Biosciences position peaked at $5K in Q3 2019.
  • 67 funds tracked by Wall St. Rank held Castle Biosciences as of Q4 2019.

Based on Catalyst Capital Advisors's 13F filing for Q4 2019, filed 6 Feb 2020.